focus -WSS

focus

author：comprehensive 2025-10-02 22:26:36 - browse：441

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Children’s Hospital revives plan for pedestrian bridge

hotspot

WSS

Using force crossed my mind when examining a defiant young patient

'Vaccine

Mass General Brigham physicians react to latest merger step

Neuroscience renaissance leads to new crop of psychiatric drugs

Scientific mystery highlights the blind spots in genomics databases

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

leisure time

focus

explore

Jerome Adams on the need for new antivirals for Covid

Four alarming medical procedures we’re glad history forgot

23andMe had bad news about my health. I wish a person had delivered it

U.K. decision on ALS drug has neurologists, advocates up in arms

Walensky prepares to leave CDC — and Congress — behind

Insurer loopholes limit power of law against surprise medical bills

After affirmative action ruling, medical educators look to 'holistic review'

Cholera vaccine supplies dangerously low, outbreaks surging

ChatGPT in medicine: STAT answers readers' burning questions

Four alarming medical procedures we’re glad history forgot

focus

Medicare isn't yet testing food as medicine

Childhood vaccination ad campaign launches in the U.K.

Medicare isn't yet testing food as medicine

Change Healthcare cyberattack shows risk of industry consolidation

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Neuroscience renaissance leads to new crop of psychiatric drugs

entertainment

hotspot

explore

hotspot